At a glance
- Originator CeNeS Pharmaceuticals
- Class
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Stroke
Most Recent Events
- 15 Oct 2002 Discontinued - Preclinical for Stroke in USA (unspecified route)
- 12 Sep 2002 No development reported - Preclinical for Stroke in USA (unspecified route)
- 16 Feb 2001 Cambridge NeuroScience is now called CeNeS Pharmaceuticals